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Abstract
Background: Helicobacter pylori represents an interesting model of bacterial patho‐
genesis	given	that	most	infections	are	asymptomatic,	while	a	minority	of	infections	
cause severe gastric disease. H pylori	strain	B128	7.13	is	used	extensively	to	under‐
stand H pylori	pathophysiology.	Due	to	extensive	 restriction‐modification	systems,	
the fact that only some H pylori	strains	are	naturally	transformable,	the	inability	of	
common	plasmid	and	transposon	vectors	to	replicate	in	this	bacterium,	as	well	as	the	
limited number of antibiotic cassettes that are functional in H pylori,	there	are	rela‐
tively few genetic tools for the mutagenesis of this bacterium.
Materials and Methods: Here,	we	use	PacBio	and	Illumina	sequencing	to	reveal	the	
complete	genome	sequence	of	H pylori	B128	7.13.	Furthermore,	we	describe	a	sys‐
tem to generate markerless and scarless mutations on the H pylori chromosome using 
the	counter‐selection	marker,	galactokinase	from	Escherichia coli.
Results: We	show	that	this	mutagenesis	strategy	can	be	used	to	generate	in‐frame	
insertions,	gene	deletions,	and	multiple	independent	mutations	in	B128	7.13.	Using	
the	closed	genome	as	a	reference,	we	also	report	the	absence	of	second	site	chromo‐
somal	mutations	and/or	rearrangements	in	our	mutagenized	strains.	We	compare	the	
genome	sequence	of	H pylori	B128	7.13	with	a	closely	related	strain,	H pylori	B8,	and	
reveal	one	notable	region	of	difference,	which	is	a	1430	bp	insertion	encoding	a	H py‐
lori‐specific	DUF874	family	protein	of	unknown	function.
Conclusions: This article reports the closed genome of the important H pylori	B128	
7.13 strain and a mutagenesis method that can be adopted by researchers as an alter‐
native strategy to generate isogenic mutants of H pylori in order to further our under‐
standing of this bacterium.
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1  | INTRODUC TION
In contrast to Escherichia coli, Helicobacter pylori supports efficient 
double	recombination	in	the	absence	of	an	exogenous	recombinase1 
and	 some	 strains	 are	 naturally	 competent	 for	 the	 uptake	 of	 DNA.	
However,	 due	 to	 the	 presence	 of	 multiple	 restriction‐modification	
systems2 and the inability of H pylori to support the replication of com‐
mon	plasmid	and	transposon	vectors,	there	is	a	need	to	expand	the	
toolbox	for	the	mutagenesis	of	H pylori.	Although	many	H pylori genes 
have	been	characterized	by	cloning	and	expression	in	laboratory	E coli 
strains,	 expression	 of	 some	H pylori proteins can be deleterious to 
E coli3,4 and so prevents their characterization. Traditional methods 
for H pylori	mutagenesis	often	 involve	multiple	cloning	steps,	which	
precede	transformation	with	donor	DNA	to	generate	mutants	marked	
with an antibiotic resistance cassette at the target loci.5	 However,	
integration of an antibiotic resistance cassette introduces pitfalls to 
subsequent	phenotypic	analysis	of	isolated	mutants	as	antibiotic	re‐
sistance determinants can introduce polar effects on downstream 
gene	expression.6	Furthermore,	these	conventional	approaches	limit	
the	ability	to	introduce	multiple	mutations,	due	to	the	lack	of	available	
antibiotic resistance cassettes for use in H pylori.	 Thus,	 counter‐se‐
lectable markers emerged as a powerful tool that enabled negative 
selection	for	the	removal	of	gene	products,	whose	expression	is	toxic	
in the presence of certain substrates. Counter‐selection methods are 
now widely accepted as a superior mutagenesis strategy to generate 
markerless and scarless mutations in various important pathogens.7,8
Previously,	Copass	et	al	developed	a	sucrose‐based	counter‐se‐
lection method that utilized the kanamycin resistance cassette and 
the sacB gene from Bacillus subtilis for the introduction of unmarked 
mutations in H pylori	 strain	G27.10	Although	 this	 counter‐selection	
method has been successfully implemented to generate unmarked 
mutations in H pylori,2	high	frequency	spontaneous	mutations	that	
give rise to sucrose resistance have been reported by multiple 
groups,	 ultimately	 hindering	 the	 use	 of	 this	 system.11	 A	 counter‐
selectable marker based on streptomycin susceptibility was also 
developed for H pylori	mutagenesis,	yet	 this	 requires	streptomycin	
resistance	in	the	host	strain,	cloning	of	two	mutagenic	plasmids	and	
a two‐step transformation method.4,11	To	overcome	these	extensive	
cloning	steps,	Debowski	et	al,	developed	a	mutagenic	system	com‐
bining	streptomycin	susceptibility	with	the	difH/XerH	excision	and	
recombination system in H pylori to generate markerless gene de‐
letions in a single transformation step.12	However,	XerH‐mediated	
excision	of	the	mutagenic	cassette	resulted	in	a	40‐bp	scar	region	at	
the	target	site,	limiting	its	effectiveness	in	generating	in‐frame	mu‐
tations	within	protein‐coding	sequences.	Therefore,	there	remains	a	
need to develop alternative mutagenesis strategies to optimize the 
generation of markerless and scarless isogenic mutants.
Here,	we	describe	 an	 improved	 counter‐selection	mutagenesis	
strategy in the H pylori	 strain	 B128	 7.13,	which	 requires	 only	 one	
cloning step and a single transformation to generate the desired 
markerless	 and	 scarless	 mutant	 strains.	 To	 do	 this,	 we	 used	 the	
counter‐selectable marker galactokinase (galK) gene from E coli. This 
gene	has	been	used	 to	generate	markerless	mutations	 in	bacteria,	
such as Mycobacterium smegmatis and Mycobacterium tuberculosis.7 
galK	 encodes	 galactokinase,	 an	 enzyme	 responsible	 for	 catalyz‐
ing the phosphorylation of galactose to galactose‐1‐phosphate. 
Additionally,	GalK	 can	 also	phosphorylate	 the	 galactose	 analogue,	
2‐deoxy‐galactose	 (2‐DOG),	 leading	to	the	production	of	2‐deoxy‐
galactose‐1‐phosphate,	 which	 cannot	 be	 further	 metabolized	 by	
H pylori	 leading	 to	 a	 buildup	 of	 toxic	 levels	 and	 subsequent	 cell	
death.7	We	show	that	GalK	expression	in	H pylori confers sensitivity 
to	2‐deoxy‐galactose	 (2‐DOG).	 Thus,	we	 synthesized	a	mutagene‐
sis gene module comprising a codon‐optimized antibiotic resistance 
cassette,	 encoding	 either	 kanamycin	 or	 apramycin	 resistance,	 and	
the galK gene under the control of the strong H pylori flaA flagel‐
lin promoter.13	Using	H pylori	strain	B128	7.13,	we	have	shown	that	
this counter‐selection method can be used to introduce multiple 
genomic	modifications,	 such	 as	 the	 insertion	of	 in‐frame	 epitopes	
and	deletion	of	target	genes.	Moreover,	we	show	that	this	strategy	
can be used to manipulate the H pylori genome at multiple loci by 
consecutive	 rounds	of	mutagenesis,	 avoiding	 the	conventional	 ap‐
proach	of	introducing	multiple	antibiotic	resistance	markers.	Lastly,	
we	reveal	the	first	fully	assembled	whole	genome	sequence	of	H py‐
lori	strain	B128	7.13,	enabling	genome‐wide	analysis	of	our	mutant	
strains,	which	confirms	the	presence	of	our	markerless	and	scarless	
mutations in the absence of second site mutations.
2  | METHODS
2.1 | Bacterial strains and media
Helicobacter pylori	B128	7.13	(cagPAI+/T4SS+) is a mouse‐colonizing 
strain that has been described previously.14 H pylori strains were rou‐
tinely	 cultured	on	either	horse	blood	agar	 (HBA)	or	 in	brain	heart	
infusion	broth	(BHI;	Oxoid)	containing	a	modified	Skirrow's	selective	
supplement	(comprising	10	µg/mL	vancomycin,	25	ng/mL	polymyxin	
B,	5	µg/mL	trimethoprim,	and	2.5	μg/mL	amphotericin	B)	according	
to standard procedures.15 Medium was supplemented with 25 μg/
mL	kanamycin	or	50	μg/mL	apramycin,	as	required.	E coli DH5α was 
propagated	on	Luria‐Bertani	agar	or	 in	broth	with	 the	appropriate	
antibiotic.	 When	 necessary,	 HBA	 was	 supplemented	 with	 0.25%	
2‐DOG.
2.2 | Protein analyses
Whole	cell	lysates	were	resuspended	in	2×	Laemmli	Buffer	(Sigma)	and	
boiled	for	5	minutes.	Proteins	were	visualized	by	Western	immunob‐
lotting after sodium dodecyl sulfate polyacrylamide gel electropho‐
resis	 (SDS‐PAGE)	 on	 precast	 polyacrylamide	 protein	 gels	 (NuPAGE	
4%‐12%	Bis‐Tris/MES,	Invitrogen),	as	described	previously.16 Proteins 
were	transferred	onto	nitrocellulose	membrane	using	the	iBLOT	(Life	
Technologies). H pylori	 proteins	 were	 reacted	 with	 rabbit	 anti‐CagA	
serum 17	 (1:2000	 dilution).	 Secondary	 alkaline	 phosphatase‐conju‐
gated	goat	anti‐rabbit	antibodies	and	NBT/BCIP	(Nitro	blue	tetrazolium	
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chloride/5‐Bromo‐4‐chloro‐3‐indolylphosphate,	Sigma)	were	used	to	
detect	antibody‐CagA	complexes.
2.3 | Molecular biology techniques and plasmid 
construction
Phusion	High‐Fidelity	DNA	 polymerase	 (Finnzymes),	DNA‐modi‐
fying	enzymes	 (Fermentas),	plasmid	mini‐prep,	genomic	DNA	ex‐
traction,	and	PCR/gel	extraction	kits	(Qiagen)	were	used	according	
to	the	manufacturer's	instructions.	Oligonucleotides	were	synthe‐
sized	by	Alta	Bioscience,	Birmingham.	Where	necessary,	plasmids	
were maintained and propagated from E coli DH5α.	DNA	was	se‐
quenced	by	 the	Sanger	method	by	 the	University	of	Birmingham	
functional genomics facility. Plasmids and oligonucleotides used 
in	 this	 study	 are	 listed	 in	 Table	 1	 and	 Table	 S2,	 respectively.	 To	
construct	pCagAKO,	an	overlap	PCR	approach	was	used.	For	this,	
DNA	fragments	encoding	the	3′	and	5′	ends	of	the	CagA	gene	were	
amplified	 using	 primers	 CagA3′EcoRI_F	 with	 CagA3′OE_R	 and	
CagA5′OE_F	with	CagA5′BamHI_R,	respectively.	In	each	reaction,	
one of the primers contained 30 nucleotides of complementary 
CagA	 sequence	 so	 that	 both	 primers	 encoded	 a	 homologous	 re‐
gion	of	 the	DNA	sequence	 flanking	cagA (overlap). H pylori	B128	
7.13	genomic	DNA	was	used	as	the	PCR	template.	Two	PCR	frag‐
ments	were	combined	in	a	subsequent	overlap	PCR	reaction	with	
CagA3′EcoRI_F	and	CagA5′BamHI_R	primers,	generating	a	916	bp	
fragment.	 This	 fragment	was	 digested	with	 EcoRI‐BamHI	 and	 li‐
gated	into	pAERP3,	digested	with	the	same	enzymes,	to	generate	
plasmid	pCagAKO.
2.4 | Gene synthesis
GeneArt	(ThermoFisher	Scientific)	or	Gene	Synthesis	(Biobasic)	and	
the	backbone	vectors	pUC57	and	pMA	were	used	where	indicated	
for codon optimization for H pylori	and	for	de	novo	DNA	synthesis,	
respectively.	 The	 GenBank	 accession	 number	 for	 the	 protein	 se‐
quence	of	GalK	in	this	study	is	ABC98037.1.
2.5 | Generation of isogenic mutants using counter‐
selection
Approximately	500	ng	of	plasmid	DNA	was	transformed	into	H pylori 
B128	7.13	by	electroporation,	as	described	previously.18 Transformants 
were	 selected	 on	 HBA	 plates,	 containing	 the	 appropriate	 antibiotic	
(positive	selection).	Following	a	4‐	to	5‐day	incubation	period,	4‐6	anti‐
biotic‐resistant	colonies	were	patch	plated	onto	fresh	HBA	plates	con‐
taining the appropriate antibiotic and incubated for 1‐2 days. Patches 
were	then	passaged	onto	half	of	a	fresh	HBA	plate,	with	no	selection.	
The	 following	day,	H pylori growth was collected using a sterile cot‐
ton	swab,	suspended	in	0.5	mL	of	BHI	broth	and	0.1	mL	aliquots	were	
plated	onto	HBA	plates	supplemented	with	0.25%	2‐DOG	 (negative	
selection).	Following	a	4‐	to	5‐day	incubation	period,	2‐3	colonies	were	
picked	from	each	of	the	original	4‐6	antibiotic‐resistant	colonies	and	
patched	onto	fresh	HBA	plates	containing	0.25%	2‐DOG.	The	follow‐
ing	day,	PCR	was	performed	on	each	patch	to	confirm	the	presence	of	
the	desired	mutation.	To	do	this,	growth	was	harvested	from	one	edge	
of	 the	patch	and	 resuspended	 in	50‐100	µL	of	10%	Chelex	 solution	
(10%	Chelex	100	resin	[BioRad],	50	mM	Tris,	pH	10.5).	This	suspension	
was	incubated	at	56°C	for	30	minutes	and	centrifuged	at	11	000	g for 
1	minute	to	pellet	the	Chelex	beads.	Supernatant	(40‐90	µL)	contain‐
ing	bacterial	DNA	was	transferred	to	a	new	tube	and	1‐2	µL	was	used	
immediately	in	a	PCR,	or	stored	at	−20°C.	The	remainder	of	the	H pylori 
growth	was	passaged	onto	a	HBA	plate,	without	 selection.	The	 fol‐
lowing	day,	growth	from	colonies	that	were	positive	by	PCR	screening	
were	harvested	and	stored	at	−80°C	in	15%	BHI‐glycerol	medium.
2.6 | Genome sequencing
Whole	 genomes	 were	 sequenced	 by	 MicrobesNG,	 University	
of	 Birmingham	 using	 the	 MiSeq	 Illumina	 platform.	 The	 Pacific	
Biosciences	 (PacBio)	 platform	 was	 used	 for	 de	 novo	 sequencing	
of H pylori	 B128	7.13	 by	 the	Centre	 for	Genomic	Research	 (CGR),	
University	 of	 Liverpool.	 Briefly,	 H pylori	 B128	 7.13	 genomic	 DNA	
was	extracted	using	the	Qiagen	Blood	DNeasy	kit,	according	to	the	
Strain or plasmid Relevant genotype or sequence Reference
Bacterial	strains
Escherichia coli DH5α fhuA2 Δ(argF‐lacZ)U169 phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 
thi‐1 hsdR17
NEB
Helicobacter pylori	B128	7.13 cagPAI+/T4SS+ 22
Bacterial	plasmids
pAERP2 Mutagenesis gene module containing 
DNA	sequence	to	insert	the	2W1S	
epitope into napA	(Aprar)
This study
pAERP3 Mutagenesis gene module containing 
DNA	sequence	to	insert	the	2W1S	
epitope into cagA	(Kanr)
This study
pCagAKO pAERP3	derivative	containing	DNA	
sequence	to	delete	cagA cloned 
between EcoRI‐BamHI sites
This study
TA B L E  1  Bacterial	strains	and	plasmids	
used in this study
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manufacturer's	instructions.	An	average	of	10	µg	of	DNA	was	sup‐
plied	to	CGR	for	sequencing.	Supplied	material	was	purified	with	1×	
cleaned	 Ampure	 beads	 (Agencourt),	 and	 the	 quantity	 and	 quality	
were	 assessed	 using	Nanodrop	 and	Qubit	 assays.	 In	 addition,	 the	
fragment analyzer (using a high sensitivity genomic kit) was used 
to	determine	the	average	size	of	the	DNA.	The	DNA	was	used	di‐
rectly	without	shearing.	DNA	was	treated	with	Exonuclease	V11	at	
37°C	for	15	minutes.	The	ends	of	the	DNA	were	repaired	as	follows.	
Samples	were	incubated	for	20	minutes	at	37°C with damage repair 
mix	supplied	in	the	SMRTbell	library	kit	(Pac	Bio).	This	was	followed	
by a 5‐minute incubation at 25°C	with	 end	 repair	 mix.	 DNA	was	
cleaned	using	1:1	volume	ratio	of	Ampure	beads	and	70%	ethanol	
washes.	DNA	was	ligated	to	adapter	overnight	at	25°C.	Ligation	was	
terminated	by	 incubation	at	65°C	for	10	minutes	 followed	by	exo‐
nuclease treatment for 1 hour at 37°C.	 The	 SMRTbell	 library	was	
purified	with	1:1	volume	ratio	of	Ampure	beads.	Size	selection	was	
performed	on	Sage	blue	pippin	prep	using	0.75%	agarose	cassette	
and	S1	marker	using	a	cutoff	of	6	kb.	The	 final	SMRT	bell	was	 re‐
covered	as	before	and	quantified	by	Qubit	assay	and	fragment	ana‐
lyzer.	SMRTbell	library	was	annealed	to	sequencing	primer	at	values	
predetermined	 by	 the	Binding	Calculator	 (Pac	Bio)	 and	 a	 complex	
made	with	 the	 DNA	 polymerase	 (P6/C4	 chemistry).	 The	 complex	
was	bound	to	Magbeads,	and	this	was	used	to	set	up	the	required	
number	of	SMRT	cells	for	the	project.	Sequencing	was	done	using	
360	minute	movie	times.
2.7 | Bioinformatic analyses
PacBio	reads	were	assembled	de	novo	with	Canu	v1.7,19 which gen‐
erated	five	contigs.	Four	of	these	were	the	B128.713	genome	and	
one	was	 the	B128.7.13	plasmid.	The	contigs	 for	 the	genome	were	
conitguated	into	a	single	scaffolded	genome	sequence	using	Pilon.20 
The	 draft	 genome	 was	 visualized	 and	 verified	 using	 Gap5.21 The 
draft	 genome	 was	 polished	 using	 MIRA	 v4.0.2	 in	 mapping	 mode	
using	 Illumina	 reads	 from	 the	 same	sample.	Both	 the	genome	and	
plasmid	 were	 annotated	 using	 PROKKA	 v1.12.22	 DNA	 sequences	
flanking the targeted sites for mutagenesis were analyzed using 
BLASTN	 and	 visualized	 in	 EasyFig.23	 Global	 genome	 alignments	
were	visualized	using	Mauve.	All	genomic	sequences	have	been	de‐
posited	to	GenBank	(BioProject	PRJNA491697).
3  | RESULTS
3.1 | Genome sequence of B128 7.13
Helicobacter pylori	strain	B128	was	originally	isolated	from	a	human	
patient suffering from gastric ulcers.14	B128	was	subsequently	used	
to	challenge	a	Mongolian	gerbil,	which	resulted	in	the	recovery	of	an	in	
vivo adapted strain that was able to induce adenocarcinoma in gerbils 
and	was	designated	strain,	B128	7.13.24	Furthermore,	in	an	independ‐
ent	experiment,	B128	was	used	to	infect	Mongolian	gerbils	for	a	total	
of	 three	 times,	 and	 a	 resulting	 strain,	 named	B8,	was	 recovered.25 
The	genome	sequence	of	B8	has	been	assembled	and	this	strain	 is	
routinely used as a reference genome for investigators interested in 
the	biology	of	B128	7.13.26	Although	the	draft	genome	of	B128	7.13	
has	 been	 reported	 using	 Illumina	 sequencing	 technology,26,27 the 
closed	genome	of	this	strain	has	not	been	reported.	Given	that	we	
sought	 to	confirm	 the	mutations	present	 in	our	mutagenized	B128	
7.13 strains on a genome‐wide scale and given the importance of the 
B128	7.13	strain	to	the	wider	research	community,	we	used	both	the	
PacBio	 and	 Illumina	 sequencing	platforms	 to	 determine	 the	 closed	
genome	sequence	of	B128	7.13.	The	genome	consists	of	a	 circular	
chromosome	of	1,	675,	441	bp,	as	well	as	a	6,149	bp	plasmid,	which	
was	not	reported	in	the	draft	genomes	of	B128	7.13	(Figure	1).
Except	for	a	117	bp	duplication	in	a	noncoding	region,	the	B128	
7.13	plasmid	is	100%	identical	to	the	HPB8p	plasmid	from	H pylori 
B8.25	 This	 high	 level	 of	 identity	 is	 expected	 given	 that	 B128	7.13	
and	 B8	 are	 both	 derived	 from	 the	 same	 progenitor	 strain,	 B128.	
From	herein,	the	plasmid	in	strain	B128	7.13	is	named	pHP7.13.	Our	
initial	annotation	of	pHP7.13	identified	only	four	coding	sequences	
(CDS),	as	opposed	to	the	annotation	of	B8,	for	which	nine	CDS	were	
identified.25 This is most likely due to differences in the method of 
annotation	as	PROKKA	may	be	unable	to	detect	the	additional	five	
CDS	due	to	their	small	sizes	and	 localization	as	nested	CDS.	Thus,	
we	manually	annotated	pHP7.13	to	highlight	the	nine	CDS	that	have	
been	functionally	identified,25 including a cluster of conjugation mo‐
bilization proteins (mobA‐D);	a	replication	initiation	protein	A	(repA); 
two	CDS	with	homology	 to	 the	dinJ‐yafQ	 toxin‐antitoxin	 (TA)	 sys‐
tem,	described	in	E coli28;	and	two	uncharacterized	CDS	that	are	spe‐
cific	to	plasmids,	pHPB8	and	pHP7.13,	found	in	H pylori	B8	and	B128	
7.13,	respectively	(Figure	1).
In	the	B128	7.13	chromosome,	we	identified	1584	CDS,	which	
included	 622	 hypothetical	 genes	 and	 36	 tRNA,	 4	 rRNA,	 and	 1	
tmRNA	genes.	 Consistent	with	 previous	 draft	 genomes	 of	B128	
7.13,	the	genome	has	a	G	+	C	content	of	38.8%.	Due	to	the	 long	
sequence	reads	generated	by	the	PacBio	sequencing	technology,	
we	were	able,	for	the	first	time	to,	visualize	global	genome	align‐
ments	 of	 our	 B128	 7.13	 genome	with	 the	 strain	 B8	 reported	 in	
Farnbacher	et	al.25	Overall,	the	genomes	aligned	almost	perfectly	
(Figure	S1),	the	largest	region	of	difference	being	an	insertion	of	a	
1430	bp	at	position	1414705	in	B128	7.13.	This	insertion	encodes	
a duplication of a H pylori‐specific	DUF874	 family	protein	of	un‐
known	 function	 but	which	 is	 thought	 to	 encode	 a	DNA‐binding	
protein that plays a role in stress tolerance and survival in vivo.29 
For	the	purpose	of	this	study,	we	have	not	provided	a	full	anno‐
tation	 of	 the	 B128	 7.13	 genome,	 but	 have	 rather	 used	 it	 as	 the	
reference genome for our mutagenized strains generated by the 
methods described below.
3.2 | Generation of a mutagenesis gene module for 
targeted mutagenesis
To	 generate	 the	 mutagenesis	 plasmids	 pAERP2	 and	 pAERP3	
(shown	in	Figure	2),	DNA	was	synthesized	de	novo	and	codon	op‐
timized	 for	 expression	 in	 H pylori	 by	 GeneArt	 Synthesis	 (Thermo	
Fisher	Scientific)	and	Gene	Synthesis	 (BioBasic),	 respectively.	Both	
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plasmids contain the mutagenesis gene module comprising the 
144‐bp	H pylori flaA promoter13 upstream of either the apramycin 
resistance	cassette	(pAERP2)	or	the	kanamycin	resistance	cassette	
(pAERP3)	and	the	galK gene from E coli30	(Figure	2).	DNA	fragments	
containing the target mutation of interest were flanked between the 
indicated restriction sites and were located immediately upstream of 
the flaA	promoter.	Plasmids	pAERP2	and	pAERP3	contain	DNA	se‐
quences,	named	NapA‐2W1S	and	CagA‐2W1S	(Figure	2),	comprising	
331	and	561	bp	regions	of	homology	flanking	the	start	ATG	codons	
of napA (neutrophil‐activating protein)31 and cagA	(cytotoxin‐associ‐
ated	gene	A),32 respectively. In addition to these regions of homol‐
ogy,	NapA‐2W1S	and	CagA‐2W1S	DNA	sequences	contained	42	bp	
insertions	 encoding	 a	 14‐amino	 acid	 epitope	 (2W1S)	with	 the	 se‐
quence	EAWGALANWAVDSA,	which	is	recognized	by	a	subpopula‐
tion	of	T	cells	in	C57BL/6	mice.33,34	However,	for	the	purpose	of	this	
study,	the	2W1S	epitope	is	simply	used	as	a	marker	for	the	modifica‐
tion	of	the	B128	7.13	chromosome.	After	recombination,	the	2W1S	
epitope	was	inserted	after	amino	acid	positions	2	and	3	of	NapA	and	
CagA,	respectively.	Annotated	sequences	of	the	mutagenesis	gene	
modules	in	pAERP2	and	pAERP3	are	shown	in	Figure	S2.
In order to show the feasibility of using this method to medi‐
ate	 markerless,	 chromosomal	 gene	 deletions,	 we	 constructed	 the	
plasmid	pCagAKO	from	pAERP3,	as	described	in	the	Materials	and	
Methods.	The	annotated	sequence	of	pCagAKO	is	shown	in	Figure	
S2.
3.3 | Generation of isogenic mutants using a one‐
step transformation and counter‐selection method
To investigate whether the mutagenesis gene module containing galK 
can be used as a counter‐selection strategy in H pylori,	we	transformed	
plasmids	pAERP2	and	pAERP3	 into	 the	H pylori	 strain	B128	7.13.	A	
schematic	 illustration	of	 this	method	 is	 shown	 in	Figure	3.	 pAERP2	
and	pAERP3	were	designed	to	 insert	the	2W1S	epitope	 into	the	N‐
terminal	 region	 of	 NapA	 and	 CagA,	 respectively.	 Plasmids	 pAERP2	
and	pAERP3	do	not	contain	an	origin	of	replication	compatible	with	
Helicobacter	spp.,	and	so	apramycin	or	kanamycin	resistance	can	only	
be selected for through homologous recombination in which the en‐
tire plasmid is integrated onto the chromosome at the targeted mu‐
tagenesis	 site.	The	2W1S	epitope	 in	plasmids	pAERP2	and	pAERP3	
was	flanked	by	regions	of	homology	(between	0.3	and	0.6	kb)	to	the	
napA and cagA	genes,	respectively,	generating	napA‐2W1S and cagA‐
2W1S	alleles.	Thus,	this	region	of	homology	directed	single	crossover	
events at the native napA and cagA	 loci,	 resulting	 in	a	chromosomal	
F I G U R E  1   Circular representation of the Helicobacter pylori	B128	7.13	genome.	The	B128	7.13	genome	consists	of	one	circular	
chromosome	(1.67	Mbp)	and	one	plasmid	(6.149	kb).	A,	The	chromosome	is	illustrated	showing	(from	the	outside	to	inside)	the	sizes	in	bp	
(circle	1);	all	open	reading	frames	in	grey	(circle	2);	the	1584	identified	forward	(red)	and	reverse	(cyan)	ORFs,	respectively	(circle	3	and	4);	
the	tRNAs	(blue)	and	rRNAs	(green),	respectively	(circles	5	and	6);	the	plot	of	G	+	C	content	(circle	7)	and	the	plot	of	the	G	+	C	skew	(circle	
8).	The	genome	was	found	to	have	a	G	+	C	content	of	38.8%.	B,	The	plasmid	has	nine	open	reading	frames	homologous	to	the	ORFs	in	the	
H pylori	B8	plasmid.	These	include	(clockwise)	two	ORFs	with	homology	to	the	dinJ‐yafQ	toxin‐antitoxin	(TA)	system	(cyan),	a	cluster	of	
conjugation	mobilization	proteins	mobC	(red),	mobA	(red),	mobB	(orange),	and	mobD	(orange),	a	replication	initiation	protein	A	(repA)	(cyan),	
and	two	uncharacterized	ORFs	(blue)
(A) (B)
1.67 Mbp
6.149 kb
D
inJ
MobA
MobD MobB
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duplication	 whereby	 the	 plasmid	 sequence	 encoding	 antibiotic	 re‐
sistance and the galK gene interrupt the native loci from the mutant 
alleles,	 as	 described	 previously.7 Isolated colonies were kanamycin 
or	 apramycin	 resistant	 and	 sensitive	 to	 2‐DOG.	 Antibiotic‐resistant	
isolates	were	grown	in	the	presence	of	2‐DOG	to	select	for	excision	
of	the	plasmid	sequence	and	resulted	in	two	outcomes:	resolution	to	
either	the	native	allele	or	the	mutant	allele.	In	either	scenario,	isolates	
were	kanamycin	or	apramycin	sensitive	and	2‐DOG	resistant.	Multiple	
colonies	were	then	verified	for	the	veracity	of	mutations	by	PCR	and,	
where	indicated,	by	whole	genome	sequencing	(Figure	4A).	For	each	
strain,	 the	number	of	antibiotic‐sensitive	and	2‐DOG‐resistant	colo‐
nies tested for successful recombination to the mutant allele is shown 
in	Table	S5.	On	average,	59%	of	the	screened	colonies	were	positive	
for the desired mutation. Positive clones by PCR were then submit‐
ted	to	MicrobesNG	for	whole	genome	sequencing,	and	the	resulting	
sequences	 were	 compared	 to	 the	 B128	 7.13	 parental	 strain.	 From	
herein,	strains	in	which	the	2W1S	epitope	was	successfully	inserted	
into	CagA	and	NapA	will	be	called	C‐2W	and	N‐2W,	respectively.
To test the compatibility of this method for multiple genomic 
modifications	within	 the	 same	 strain,	we	 used	 this	 system	 to	 gen‐
erate	 a	 strain	whereby	 both	 CagA	 and	NapA	 are	marked	with	 the	
2W1S	epitope.	To	do	 this,	N‐2W	was	 transformed	with	pAERP3	 in	
order to insert into cagA	the	sequence	encoding	the	2W1S	epitope.	
Kanamycin‐sensitive	 and	 2‐DOG‐resistant	 colonies	 were	 isolated	
using the counter‐selection method described above. The veracity of 
the	double	mutant	 strain,	 named	CN‐2W,	was	 confirmed	by	whole	
genome	sequencing	(Figure	4A).	Furthermore,	production	of	CagA	in	
whole	cell	 lysates	prepared	 from	C‐2W	and	CN‐2W	was	confirmed	
by	Western	 immunoblotting,	 using	 antibodies	 raised	 against	 CagA	
(Figure	4B).	In	order	to	ensure	that	the	mutagenesis	method	did	not	
cause	significant	secondary	site	mutations,	VarScan	was	used	to	iden‐
tify	 single	nucleotide	polymorphisms	 (SNPs)	and	small	 insertions	or	
deletions	 (indels)	between	the	B128	7.13	parental	strain	and	C‐2W,	
N‐2W,	and	CN‐2W.	Analyses	were	performed	using	a	stringent	90%	
cutoff	value,	which	required	at	least	90%	of	sequence	reads	to	contain	
the	SNP.	A	total	of	eight	SNPs	were	 identified	common	to	all	 three	
sequenced	 strains,	 of	 which	 six	 were	 found	 in	 coding	 regions.	 Of	
these	six	SNPs:	 four	caused	missense	mutations	 in	 the	genes	gpsA, 
HP713_00241,	and	HP713_01483;	one	caused	a	frame	shift	in	cysP_2; 
and one caused a premature stop codon in fliF	 (Table	S2).	However,	
these	mutations	were	 not	 found	 in	 all	 B128	 7.13	 isogenic	mutants	
made	in	our	laboratory	using	this	method	(data	not	shown),	suggest‐
ing that these mutations are not a result of this mutagenesis proto‐
col.	SNPs	were	also	found	that	were	unique	to	strains	C‐2W,	N‐2W,	
F I G U R E  2  Mutagenesis	plasmids	pAERP2	and	pAERP3	used	in	this	study.	Both	plasmids	have	the	Escherichia coli galK gene and either 
the	genes	encoding	apramycin	(Apra)	or	kanamycin	(Kan)	resistance	under	the	control	of	the	H pylori flaA	flagellin	promoter	(pfla).	Both	
plasmids	contain	the	target	mutations	upstream	of	the	pfla	promoter	labeled	NapA‐2W1S	(pAERP2)	or	CagA‐2W1S	(pAERP3).	In	pAERP2,	
NapA‐2W1S	contains	a	330	bp	region	of	homology	to	the	DNA	sequence	flanking	the	start	codon	of	the	neutrophil‐activating	protein	
(NapA)	(light	grey)	which	is	interrupted	by	a	42	bp	sequence	encoding	the	2W1S	epitope	(dark	grey)	inserted	at	amino	acid	position	2	in	
NapA.	In	pAERP3,	CagA‐2W1S	contains	a	561	bp	region	of	homology	to	the	DNA	sequence	flanking	the	start	codon	of	the	CagA	protein	
(light	grey),	which	is	interrupted	by	a	42	bp	sequence	encoding	the	2W1S	epitope	(dark	grey)	inserted	at	amino	acid	position	3	in	CagA.	
Restriction	sites	for	enzymes	EcoRI	and	BamHI	are	shown.	The	pAERP2	and	pAERP3	plasmids	were	used	to	generate	an	in‐frame	insertion	
of	the	2W1S	epitope	into	the	coding	regions	of	napA and cagA,	respectively
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and	CN‐2W.	A	complete	list	of	SNPs	and	their	locations	can	be	found	
in	Table	S2.	 Importantly,	no	significant	genomic	 inversions	or	 indels	
were	observed	as	a	result	of	this	mutagenesis	method.	Moreover,	the	
flanking	and	coding	sequences	of	cagA and napA remained identical 
to	those	of	the	parental	strain,	showing	that	secondary	site	mutations	
are	not	an	issue	with	this	mutagenesis	method	(Figure	4A).
In order to use this method to delete cagA	in	B128	7.13,	pCagAKO	
was transformed into H pylori	B128	7.13	following	the	mutagenesis	
protocol above. To confirm the loss of cagA, primers that annealed 
to the central portion of cagA were used in PCRs to screen candidate 
isolates	 that	were	 kanamycin	 sensitive	 and	 2‐DOG	 resistant	 (data	
not	shown).	An	isolate	that	was	confirmed	by	PCR	for	the	absence	of	
cagA	was	also	tested	using	Western	immunoblotting	to	ensure	the	
absence	of	CagA	in	whole	cell	lysates	(Figure	4B).
4  | DISCUSSION
Here,	we	reveal	the	closed	genome	sequence	of	H pylori	strain	B128	
7.13 and a method for generating genomic markerless and scarless 
isogenic mutants. H pylori	B128	7.13	 is	an	 important	strain	 for	 the	
study of H pylori	physiology,	both	in	vitro	and	in	vivo.14,26 Consistent 
with previous reports of H pylori	 genomes,	 including	 the	draft	 ge‐
nomes	of	B128	7.13	that	were	recently	published,14,26,27	 the	B128	
7.13	genome	size	is	relatively	small	(1.67	Mbp)	in	comparison	to	other	
gastrointestinal	pathogens,	 such	as	E coli 35 and S.	Typhimurium,36 
where	 larger	genomes	are	typically	observed	(5‐6	Mbp).	The	com‐
paratively small genome size of H pylori	 is	 likely	 due	 to	 extensive	
adaptation	to	the	human	stomach	over	thousands	of	years,	and	we	
refer	the	reader	to	the	extensive	literature	discussing	this	topic.37,38 
The	G	+	C	content	of	the	B128	7.13	genome	was	found	to	be	38.8%	
with	1584	CDS.	The	annotation	described	by	Noto	et	al	showed	a	
lower	number	(1485)	of	CDS	(Table	S1),	which	could	be	due	to	dif‐
ferences	in	the	programs	used	for	annotation.	Alternatively,	this	dif‐
ference	could	be	attributed	to	the	long‐read	sequencing	technology	
used here vs the limitations of the short‐read technology available 
previously.	For	example,	the	early	termination	of	genes	due	to	short	
reads may lead to an increase in the numbers of pseudogenes identi‐
fied	and	therefore	a	reduction	in	true	CDS.	A	notable	finding	of	the	
current	work	was	a	1430	bp	insertion	present	in	the	genome	of	B128	
F I G U R E  3  Schematic	illustration	of	the	mutagenesis	strategy	used	in	this	study.	Briefly,	approximately	500	ng	of	plasmid	DNA	was	
transformed into H pylori	electrocompetent	cells.	Transformants	were	selected	on	HBA	plates	containing	the	appropriate	antibiotic,	and	
4‐6	colonies	were	patch	plated	onto	fresh	HBA	plate	containing	antibiotic.	These	patches	were	then	spread	onto	half	a	HBA	plate	with	no	
selection,	and	after	a	1‐day	incubation	period,	growth	was	resuspended	in	0.5	mL	of	BHI	broth.	0.1	mL	aliquots	were	then	plated	onto	HBA	
containing	0.25%	2‐DOG.	After	4‐	to	5‐day	incubation,	4‐6	colonies	from	each	original	antibiotic‐resistant	colony	were	patch	plated	onto	
HBA	containing	0.25%	2‐DOG	and	each	patch	was	tested	by	PCR	for	the	desired	mutation
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7.13,	which	is	absent	in	strain	B8.	This	insertion	encodes	a	duplica‐
tion of an H pylori‐specific	DUF874	family	protein,	which	has	been	
implicated in survival of H pylori in a mouse model29 and thus could 
have	arisen	during	adaptation	of	B128	to	the	gerbil.
The mutagenesis approach taken in this study involves one clon‐
ing	step	and	a	single	transformation,	followed	by	positive	and	neg‐
ative selection to isolate markerless and scarless isogenic mutants 
of	B128	7.13.	Although	the	counter‐selectable	marker	sacB, which 
confers	sensitivity	to	sucrose,	has	been	used	by	multiple	groups	to	
generate scarless mutants in H pylori,2,10,39 there have been reports 
of sacB inactivation and spontaneous resistance to sucrose in H py‐
lori and other bacteria.11,40,41 This has prompted the use of alterna‐
tive	markers,	such	as	galK, which does not seem to be as prone to 
inactivation as sacB.42	Nevertheless,	 this	 has	 not	 been	 systemati‐
cally studied in H pylori and therefore warrants further investigation. 
Given	that	transformation	efficiency	can	be	influenced	by	the	antibi‐
otic resistance cassette used for selection in H pylori,	we	synthesized	
plasmids	pAERP2	and	pAERP3	to	encode	the	kanamycin	and	apra‐
mycin	 resistance	 cassettes,	 respectively.	 However,	 no	 significant	
differences were observed between transformation efficiencies of 
B128	 7.13	with	 either	 pAERP2	 or	 pAERP3	 (data	 not	 shown).	 The	
mutagenesis	gene	modules	 in	both	pAERP2	and	pAERP3	comprise	
the	 strong,	 constitutive	 flaA	 promoter,	which	mediates	 expression	
of the respective antibiotic resistance cassette and the galK gene 
(Figure	2).	The	EcoRI	 and	BamHI	 restriction	 sites	upstream	of	 the	
mutagenesis	gene	module	enable	cloning	of	DNA	sequences	homol‐
ogous	to	the	target	loci	of	interest.	In	our	hands,	0.3‐0.6	kb	of	DNA	
sequence	homologous	to	the	target	loci	(Figure	2)	was	sufficient	to	
mediate	homologous	recombination	and	subsequent	 integration	of	
the	entire	plasmid	at	 the	chromosomal	 locus.	However,	 increasing	
F I G U R E  4  Comparison	of	mutant	strains	with	the	B128	7.13	parental	strain,	using	nucleotide	alignments	and	Western	immunoblotting.	
A,	Nucleotide	alignments	and	open	reading	frame	(ORF)	representation	of	the	parental	strain	B128	7.13	(WT)	and	mutant	strains	that	carry	
an	N‐terminal	insertion	of	the	2W1S	epitope	in	cagA	(C‐2W),	napA	(N‐2W)	or	both	cagA and napA	(CN‐2W)	are	illustrated	using	Easyfig.29 
For	simplicity,	ORFs	flanking	cagA (green arrow) and napA (orange arrow) are unlabeled and shown as light grey arrows. Dark grey bands 
between	the	indicated	strains	denote	regions	of	identity.	White	gaps	mark	the	insertion	of	the	sequence	encoding	the	2W1S	epitope	in	
the	N‐terminal	region	of	cagA	(C‐2W),	the	N‐terminal	region	of	napA	(N‐2W)	and	in	both	the	N‐terminal	regions	of	cagA and napA	(CN‐2W),	
as	a	result	of	the	targeted	mutagenesis	strategy.	B,	Western	immunoblotting	analyses	of	CagA	production	in	cell	lysates	of	the	B128	7.13	
parental	strain	(WT),	the	strain	that	contains	N‐terminal	insertion	of	2W1S	in	the	CN‐2W	strain	and	the	strain	where	CagA	is	deleted	
(ΔcagA).	CagA	localization	was	detected	using	anti‐CagA	antibody	and	is	indicated	by	an	arrow	at	the	molecular	weight	of	approximately	
150	kDa	(M—protein	markers,	kDa).	As	expected,	CagA	is	present	in	the	parental	B128	7.13	strain	and	the	CN‐2W	strain,	yet	is	absent	from	
the ΔcagA	strain	generated	in	this	study.	These	results	confirm	that	the	mutagenesis	strategy	has	inserted	an	in‐frame,	2W1S	epitope	at	
the	N‐terminus	of	CagA	in	the	C‐2W	and	CN‐2W	strain,	without	disrupting	the	production	of	full‐length	CagA	protein	and	has	successfully	
deleted cagA in the ΔcagA deletion strain
(A)
(B)
cagA napA
WT
N-2W
CN-2W
C-2W
WT
WT
CagA
M                WT             CN-2W          ΔcagA
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the	length	of	DNA	sequences	(up	to	1	kb)	has	been	shown	to	increase	
the	frequency	of	homologous	recombination	in	bacteria.43	Using	this	
method,	we	were	able	to	isolate	mutant	strains	that	contain	in‐frame	
insertions	in	CagA	(C‐2W),	NapA	(N‐2W)	and	both	CagA	and	NapA	
(C/N‐2W).	 Furthermore,	 using	Western	 immunoblotting,	 we	 con‐
firmed	that	C‐2W	and	C/N‐2W	were	still	able	to	produce	full‐length	
CagA	(Figure	4).	Additionally,	in	order	to	create	an	isogenic	mutant	of	
B128	7.13	lacking	cagA,	we	modified	pAERP3	to	generate	the	plas‐
mid	pCagAKO	(Figure	4).	Thus,	we	present	here	a	versatile	method	
that	can	be	used	to	generate	multiple	genomic	modifications	in	B128	
7.13.	To	confirm	the	veracity	of	mutagenized	strains,	whole	genome	
sequences	 of	 C‐2W,	 N‐2W,	 and	 C/N‐2W	were	 analyzed	 bioinfor‐
matically to ensure that there were no significant second site muta‐
tions	or	large	genomic	rearrangements.	Although	no	large	genomic	
rearrangements	or	inversions	were	evident	in	our	analyses,	VarScan	
did	highlight	a	number	of	SNPs	that	were	either	unique	to	each	de‐
rived	strain	or	were	common	between	the	strains.	The	eight	SNPs	
that	were	found	to	be	common	between	C‐2W,	N‐2W,	and	C/N‐2W	
strains	may	reflect	mutations	that	are	more	frequently	selected	for	
during	growth	under	standard	 laboratory	conditions.	For	example,	
the	SNP	present	in	fliF,	which	encodes	a	component	of	the	flagellar	
machinery,	may	be	 an	 adaptation	 to	 growth	 in	 vitro.	All	 SNPs	 are	
listed	 in	Table	S3;	most	 importantly,	 these	SNPs	do	not	 appear	 in	
all the strains that our laboratory has generated using this method 
(data not shown). This method is advantageous in comparison with 
alternative mutagenesis approaches given that only one cloning 
step	and	one	transformation	step	are	required	to	generate	scarless	
mutations.	However,	the	efficiency	of	recombination	to	the	mutant	
allele	using	this	method	is	on	average	59%,	which	is	lower	than	that	
of previously reported methods.11,12	For	comparison,	we	have	listed	
the reported efficiencies and advantages and disadvantages of the 
available mutagenesis methods in H pylori using counter‐selectable 
markers	 (Table	 S4).	 The	main	 limitation	 of	 this	method	 is	 that	we	
were unable to generate mutants in the mouse‐colonizing H pylori 
SS1	and	PMSS1	strains,44 and although kanamycin‐sensitive and 2‐
DOG‐resistant	colonies	could	be	isolated,	they	did	not	contain	the	
desired	mutations	(data	not	shown).	 It	 is	generally	known	that	SS1	
and	PMSS1	are	not	 as	easily	 amenable	 to	genetic	manipulation	as	
other H pylori strains.5	Nevertheless,	given	that	antibiotic‐resistant	
and	2‐DOG‐resistant	colonies	were	isolated,	it	is	likely	that,	with	fur‐
ther	optimization,	this	method	may	be	used	to	generate	mutants	in	
this and other less genetically tractable strains.
In	summary,	we	have	established	a	method	to	generate	isogenic	
mutants of H pylori	 strain	 B128	 7.13.	We	 have	 shown	 that	 when	
using	 this	mutagenesis	method,	 the	mutants	 have	 no	 second	 site	
mutations	within	the	flanking	regions	of	the	target	mutation,	have	
limited	 SNPs	 and/or	 indels,	 do	 not	 contain	 an	 antibiotic	 marker,	
and are amenable to successive rounds of genomic modifications. 
Furthermore,	we	report	the	closed	genome	of	B128	7.13,	which	pro‐
vides a useful resource for researchers interested in the biology of 
B128	7.13,	which	is	one	of	the	reference	strains	commonly	used	in	
mouse infection studies.
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